# Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

> **NCT05782270** · PHASE4 · RECRUITING · sponsor: **China National Center for Cardiovascular Diseases** · enrollment: 202 (estimated)

## Conditions studied

- Anticoagulation
- Coronary Endarterectomy

## Interventions

- **DRUG:** Warfarin
- **DRUG:** DAPT
- **OTHER:** CE+CABG

## Key facts

- **NCT ID:** NCT05782270
- **Lead sponsor:** China National Center for Cardiovascular Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-11
- **Primary completion:** 2025-09-25
- **Final completion:** 2026-05-30
- **Target enrollment:** 202 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05782270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05782270, "Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05782270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*